Literature DB >> 15772102

On criteria for evaluating models of absolute risk.

Mitchell H Gail1, Ruth M Pfeiffer.   

Abstract

Absolute risk is the probability that an individual who is free of a given disease at an initial age, a, will develop that disease in the subsequent interval (a, t]. Absolute risk is reduced by mortality from competing risks. Models of absolute risk that depend on covariates have been used to design intervention studies, to counsel patients regarding their risks of disease and to inform clinical decisions, such as whether or not to take tamoxifen to prevent breast cancer. Several general criteria have been used to evaluate models of absolute risk, including how well the model predicts the observed numbers of events in subsets of the population ("calibration"), and "discriminatory power," measured by the concordance statistic. In this paper we review some general criteria and develop specific loss function-based criteria for two applications, namely whether or not to screen a population to select subjects for further evaluation or treatment and whether or not to use a preventive intervention that has both beneficial and adverse effects. We find that high discriminatory power is much more crucial in the screening application than in the preventive intervention application. These examples indicate that the usefulness of a general criterion such as concordance depends on the application, and that using specific loss functions can lead to more appropriate assessments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15772102     DOI: 10.1093/biostatistics/kxi005

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  92 in total

1.  Evaluating breast cancer risk projections for Hispanic women.

Authors:  Matthew P Banegas; Mitchell H Gail; Andrea LaCroix; Beti Thompson; Maria Elena Martinez; Jean Wactawski-Wende; Esther M John; F Allan Hubbell; Shagufta Yasmeen; Hormuzd A Katki
Journal:  Breast Cancer Res Treat       Date:  2011-12-07       Impact factor: 4.872

2.  Inclusion of gene-gene and gene-environment interactions unlikely to dramatically improve risk prediction for complex diseases.

Authors:  Hugues Aschard; Jinbo Chen; Marilyn C Cornelis; Lori B Chibnik; Elizabeth W Karlson; Peter Kraft
Journal:  Am J Hum Genet       Date:  2012-05-24       Impact factor: 11.025

3.  Comment: Measures to summarize and compare the predictive capacity of markers.

Authors:  Nancy R Cook
Journal:  Int J Biostat       Date:  2010-07-06       Impact factor: 0.968

4.  Assessing risk prediction models in case-control studies using semiparametric and nonparametric methods.

Authors:  Ying Huang; Margaret Sullivan Pepe
Journal:  Stat Med       Date:  2010-06-15       Impact factor: 2.373

5.  Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population.

Authors:  Brian M Wolpin; Peter Kraft; Jihye Kim; Chen Yuan; Ana Babic; Ying Bao; Clary B Clish; Michael N Pollak; Laufey T Amundadottir; Alison P Klein; Rachael Z Stolzenberg-Solomon; Pari V Pandharipande; Lauren K Brais; Marisa W Welch; Kimmie Ng; Edward L Giovannucci; Howard D Sesso; JoAnn E Manson; Meir J Stampfer; Charles S Fuchs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-04-22       Impact factor: 4.254

Review 6.  Body mass index and colon cancer screening: the road ahead.

Authors:  Kanwarpreet Tandon; Mohamad Imam; Bahaa Eldeen Senousy Ismail; Fernando Castro
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

7.  Integrating the predictiveness of a marker with its performance as a classifier.

Authors:  Margaret S Pepe; Ziding Feng; Ying Huang; Gary Longton; Ross Prentice; Ian M Thompson; Yingye Zheng
Journal:  Am J Epidemiol       Date:  2007-11-02       Impact factor: 4.897

8.  Assessing the performance of prediction models: a framework for traditional and novel measures.

Authors:  Ewout W Steyerberg; Andrew J Vickers; Nancy R Cook; Thomas Gerds; Mithat Gonen; Nancy Obuchowski; Michael J Pencina; Michael W Kattan
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

9.  Applying the Lorenz curve to disease risk to optimize health benefits under cost constraints.

Authors:  Mitchell H Gail
Journal:  Stat Interface       Date:  2009-01-01       Impact factor: 0.582

10.  Understanding increments in model performance metrics.

Authors:  Michael J Pencina; Ralph B D'Agostino; Joseph M Massaro
Journal:  Lifetime Data Anal       Date:  2012-12-16       Impact factor: 1.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.